登录  
 加关注
查看详情
   显示下一条  |  关闭
温馨提示!由于新浪微博认证机制调整,您的新浪微博帐号绑定已过期,请重新绑定!立即重新绑定新浪微博》  |  关闭

青山妩媚

新的一年,新的心情,新的挑战,新的起点...

 
 
 

日志

 
 

BioDuro 迈向CRO之路  

2009-05-11 13:19:09|  分类: Bio-Pharma |  标签: |举报 |字号 订阅

  下载LOFTER 我的照片书  |

 

引用

燕子BioDuro 迈向成功CRO之路

China's one stop research shop

19 May 2008

John Oyler has founded a string of startups in the US, including Genta, a biotech specializing in cancer drug discovery, and Galenea, which focuses on treatments for psychiatric diseases. But in 2005 he chose China as his base to launch BioDuro, a life sciences Contract Research Organisation (CRO). He explains to Chemistry World how he has managed to turn BioDuro into one of China's leading CROs in just three years.

Why did you choose to launch a CRO in China rather than the US?

In the US over the last five years, the big pharmaceutical companies and venture capital firms have cut investment in the longer-term, riskier preclinical research that is likely to lead to truly innovative therapies.

On the other hand, building a CRO in the emerging Chinese market allows us to be involved in all stages of the research, from the basic idea to the clinical trial.

When I was CEO of Galenea about a quarter of our researchers were from India and a third from China. This made me realise that China could supply exceptionally capable scientists.

So my old friend and business partner Ma*** Tayebi and I launched and financed BioDuro. Funding our business ourselves allowed us to pursue the opportunities that we thought were the most important.

But why did you choose Beijing, when the main clients of CROs - the big multinational drug firms - have their R&D centres in Shanghai?

There are exceptionally talented scientists in Beijing. It has world class universities and research institutes, like Peking and Tsinghua universities, Peking Union Medical College, the National Institute of Biological Sciences, the National Center for the Safety Evaluation of Drugs, and the related institutes of the Chinese Academy of Sciences.

R&D centres, which only do some of big pharma's drug development work, are not the only source of business. Most of our contracts are from their US and European headquarters. And because there are fewer research organisations and CROs in Beijing, there is more chemistry and biology talent available to draw on.

By the end of this year, we will have nearly 600 chemists and biologists working for the company. Most of the world's top pharmaceutical firms are our clients. We have our business and marketing headquarters in San Diego, California. We have a team of more than 20 senior scientists leading the firm, many of whom used to be at multinationals like Merck and Pfizer.

Is it easy to attract top scientists to China?

Most are overseas Chinese who had long wanted to contribute the scientific development of their home country once there were suitable opportunities. And I am always on a mission to persuade the best scientist join us.

One example is a senior scientist at Merck - Steven Hutchins. I first met him when he gave a talk [in the US] about life science development. Then, after his talk we had a long talk and he saw that our work here was aligned with his vision. Later, after we met in China, he decided to join us. Likewise Jason Zhang joined us recently from Neurocrine in San Diego where he has watched us grow over the last few years. Jason returned for the opportunity [to work for BioDuro], but also to be closer to his parents and family. For the senior scientists, they understand that there may be more responsibility and better research opportunities in China.

Multinationals choose Chinese CROs to keep costs down, but you have spent a lot of money hiring scientists and establishing facilities. Do you still have the cost advantage?

First I would say big pharma is not entirely driven by costs. It also depends on the quality of work you can offer and whether they want an integrated solution or simply some easy research.

The cost of doing research here can be a third to a quarter of that in the US or Europe. Sure - BioDuro will not be the cheapest option, but we have already established a strong reputation for providing integrated solutions, creative problem solving, adhering to environmental, health, and safety standards, and exceeding client expectations.

But the best thing about doing research in China is the scientists. They have a real thirst for knowledge, and an incredibly humble, yet can-do approach to challenges. There is nothing that they cannot learn and no challenge that cannot be overcome.

I think all of these factors stimulate multinational pharmaceuticals to engage in contract research in China - not costs alone.

Hepeng Jia

John Oyler's BioDuro is already one of China's leading Contract Research Organisations (CROs) ? BioDuro

编译:

BioDuro 迈向成功CRO之路

John Oyler在美国建立了一系列新公司,包括Genta(一家专门开发抗癌药物的生物科技公司)和Galenea(专门从事治疗精神疾病)。但是2005年他选择在中国创建BioDuro公司――一家生命科学研究外包服务机构(CRO)。他向《化学世界》杂志阐述了,他如何在短短三年时间内将BioDuro变成中国CRO的领军人物。

为什么你要选择中国来开展CRO业务,而不是在美国呢?

在过去五年里,美国的那些大制药公司和风险投资公司都削减了对周期较长、风险较高的临床前研究的投资,但正是通过这些研究很可能会发现真正创新性的治疗方法。另一方面,在中国这个新兴市场成立CRO可以使我们接触研究的所有阶段,从基本构思到临床试验。

当我还是Galenea的CEO时,我们的研究人员约有四分之一来自于印度,三分之一来自于中国。这使我意识到中国能提供非常有才华的研究人员。因此我的老朋友及生意伙伴Ma*** Tayebi和我组建了这家BioDuro。为了增强我们的业务,我们追求我们认为最重要的机会。

但是你们为什么选择北京呢,CRO的主要客户----那些国际大制药公司都在上海设立其研发中心?

北京有非常优秀的研究人员。有世界级的大学和研究所,像北京大学和清华大学,北京协和医科大学,北京生命科学研究所,国家药品安全评审中心及中国科学院的一些研究所。

研发中心只做一些大制药公司的药品研发工作,而这并非我们唯一的业务。我们大部分的研究外包服务订单来自这些公司位于美国和欧洲的总部。而且因为北京的研究机构和CRO机构比较少,所以有更多化学和生物方面的人才可以利用。

在今年年底前,我们公司将发展成约600名合成人员和生物人员的规模。很多世界顶级制药公司都是我们的客户。我们的业务和市场总部在加利福尼亚州圣地亚哥。由20多位资深研究员组成的研究小组领导,他们中的很多人曾在跨国公司默克和辉瑞工作。

将顶级研究人员吸引到中国,是否比较难?

大部分是海外华人,一旦有合适的机会他们始终希望为他们祖国的科学发展贡献力量。而我的使命就是说服最优秀的研究人员加入我们。

Steven Hutchins曾是默克公司的一位资深研究员。我第一次遇到他(在美国)是在他关于生命科学发展的一次演讲上。在他演讲结束后,我们进行了一次长谈,他发现我们在这儿(中国)的工作与他的设想吻合。后来,当我们在中国又一次见面以后,他决定加入我们。同样,Jason Zhang最近也离开圣地亚哥的Neurocrine公司而加入了我们,他目睹了我们在近年内的成长。因为在BioDuro的这个工作机会,Jason回到了中国,同时也是为了离父母和家人更近。对于高级研究员,他们明白在中国工作要承担更多责任,也有更好的研究机会。

跨国公司选择中国CRO是为了降低成本,但是你却花很多钱雇研究员并筹建设施场地。这样的话你还有成本优势吗?

首先,我要说,大制药公司的业务并非完全由成本决定。它们是否选择你,同样取决于你的业务质量及他们到底是想要一种综合性的解决方案还是仅仅需要做一些简单研究。

这儿的研发成本可能是美国或欧洲的1/3-1/4。当然,BioDuro不是最便宜的选择,但我们已经在提供综合性解决方案、创造性解决问题、坚持环境、健康和安全标准,及满足客户预期以外的要求方面建立了良好信誉。

不过在中国进行研发的最大优势在于研究人员。他们对于知识有一种真正的渴望,十分谦逊,还能完成艰巨的任务。没有他们学不会的知识,没有他们克服不了的困难。

我认为所有这些因素都促使跨国制药公司来中国进行这种研究外包服务,并不只是成本方面的考虑。(丁香)

  评论这张
 
阅读(466)| 评论(0)

历史上的今天

评论

<#--最新日志,群博日志--> <#--推荐日志--> <#--引用记录--> <#--博主推荐--> <#--随机阅读--> <#--首页推荐--> <#--历史上的今天--> <#--被推荐日志--> <#--上一篇,下一篇--> <#-- 热度 --> <#-- 网易新闻广告 --> <#--右边模块结构--> <#--评论模块结构--> <#--引用模块结构--> <#--博主发起的投票-->
 
 
 
 
 
 
 
 
 
 
 
 
 
 

页脚

网易公司版权所有 ©1997-2018